CYTOMX THERAPEUTICS, INC. (NASDAQ:CTMX) Files An 8-K Results of Operations and Financial Condition

Item 2.02.Results of Operations and Financial Condition

On January 10, 2017, CytomX Therapeutics, Inc. (the Company) will
be providing a corporate update, including the Companys
preliminary (unaudited) cash balance of $182 million as of
December 31, 2016, at the 35^th Annual J.P. Morgan
Healthcare Conference (the JPMorgan Conference).

The information in this Item 2.02, including Exhibit 99.1, shall
not be deemed filed for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act) or otherwise
subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except
as expressly set forth by specific reference in such a filing.

Item 7.01Regulation FD Disclosure

As referenced above, the Company will be giving a presentation at
the JPMorgan Conference on January 10, 2017. A copy of the
presentation, including a slide setting forth certain cautionary
language intended to qualify the forward-looking statements
included in the presentation, is furnished as Exhibit 99.1 to
this Current Report and is incorporated herein by reference.

The information in this Item 7.01, including Exhibit 99.1, shall
not be deemed filed for purposes of Section 18 of the Security
Exchange Act of 1934, as amended (the Exchange Act) or otherwise
subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except
as expressly set forth by specific reference in such filing.

Item 9.01.Financial Information and Exhibits

(d) Exhibits

About CYTOMX THERAPEUTICS, INC. (NASDAQ:CTMX)

CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company. The Company is engaged in the development of a class of antibody therapeutics based on its Probody technology platform. It uses its platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against a range of targets. A Probody therapeutic consists of three components produced as a single protein by standard antibody production methodology: an active anti-cancer antibody, a mask for the antibody and a protease-cleavable linker. Its Probody product candidate, CX-072, is directed against programmed death-ligand 1 (PD-L1). CX-072 is based on a monoclonal antibody targeting PD-L1. Its product candidate, CX-2009, is directed against the target CD-166. It is developing a programmed cell death protein 1 (PD-1) Probody therapeutic as an additional approach to block the PD-L1/PD-1 pathway. It is also conducting Integrin alpha-3 PDC program.

CYTOMX THERAPEUTICS, INC. (NASDAQ:CTMX) Recent Trading Information

CYTOMX THERAPEUTICS, INC. (NASDAQ:CTMX) closed its last trading session up +0.14 at 11.36 with 46,031 shares trading hands.